Association between hormonal genetic polymorphisms and early-onset prostate cancer

Prostate Cancer Prostatic Dis. 2005;8(1):95-102. doi: 10.1038/sj.pcan.4500785.

Abstract

We investigated the association between seven polymorphisms in four candidate genes involved in vitamin D and androgen metabolism with early-onset prostate cancer (CaP) risk. The polymorphisms were genotyped in 288 UK males who were diagnosed with CaP at the age of 55 y or younger and up to 700 population-based controls. An additional 50 cases (not selected for age) and 76 controls were also genotyped. Short (< or =22 repeats) AR (CAG)(n) repeats were associated with a significantly reduced risk of early onset CaP (OR 0.68, 95% CI 0.50-0.91) compared with men with long (> 22) repeats. Men homozygous for the leucine variant of SRD5A2 p.89V > L were also found to be at a significantly increased risk of CaP compared with men who were homozygous for the valine allele (OR 1.84, 95% CI 1.15-2.98). No associations were found with the AR (GGC)(n), CYP17 Msp A1 I, VDR Taq I, SRD5A2 (TA)(n) and p.49A >T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men.

MeSH terms

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics*
  • Adult
  • Age of Onset
  • Androgens / metabolism
  • Antioxidants / metabolism
  • Case-Control Studies
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology*
  • Receptors, Androgen / genetics*
  • Trinucleotide Repeats
  • United Kingdom
  • Vitamin D / metabolism

Substances

  • Androgens
  • Antioxidants
  • Receptors, Androgen
  • Vitamin D
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase